Trinity Biotech plc (NASDAQ:TRIB) Stock Position Increased by Hunter Associates Investment Management LLC

Hunter Associates Investment Management LLC boosted its position in shares of Trinity Biotech plc (NASDAQ:TRIB) by 7.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 359,810 shares of the company’s stock after buying an additional 26,100 shares during the quarter. Hunter Associates Investment Management LLC owned 4.72% of Trinity Biotech worth $390,000 at the end of the most recent quarter.

Trinity Biotech Stock Performance

Shares of NASDAQ:TRIB opened at $2.02 on Wednesday. The company has a market capitalization of $15.39 million, a PE ratio of -0.75 and a beta of 1.20. The stock has a fifty day moving average of $1.67 and a 200-day moving average of $2.04. Trinity Biotech plc has a one year low of $1.05 and a one year high of $3.55.

Trinity Biotech (NASDAQ:TRIB) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.10. The company had revenue of $15.84 million during the quarter, compared to analysts’ expectations of $15.75 million. As a group, research analysts forecast that Trinity Biotech plc will post -1.91 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, StockNews.com started coverage on shares of Trinity Biotech in a report on Friday, August 30th. They issued a “buy” rating for the company.

Trinity Biotech Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.